跳至主要内容
临床试验/NCT01037452
NCT01037452已完成2 期

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group Proof-of-Concept Trial to Assess Relief of Meal Induced Heartburn by a Combination of Lansoprazole 15 mg and Antacid Versus Lansoprazole 15 mg and Antacid (Calcium Carbonate and Magnesium Hydroxide) Alone

Novartis0 个研究点目标入组 120 人开始时间: 2009年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Novartis
入组人数
120
主要终点
Measure: Number of Participants With no Heartburn (Post Treatment) Following Consumption of Heartburn-inducing Meal

研究概览

简要总结

This study will investigate the safety and efficacy of an antacid/Lansoprazole combination product for the relief of heartburn after consuming a heartburn-inducing meal.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Experiencing heartburn in the past month if untreated
  • Having heartburn that responds to heartburn medication
  • Be willing to discontinue the use of heartburn treatment for 7 days prior to inclusion in the study.

排除标准

  • Having history of erosive esophagitis or gastroesophageal reflux disease (GERD) diagnosed by a physician and confirmed by testing (endoscopy)
  • Be unwilling to take only the study medication, and antacid provided as a rescue medication for relief of acute heartburn during the study.
  • "Other protocol-defined inclusion/exclusion criteria may apply"

研究组 & 干预措施

Placebo

Placebo Comparator

Placebo

干预措施: Placebo (Drug)

Combination product

Experimental

Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet

干预措施: Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg (Drug)

PPI alone

Active Comparator

Lansoprazole

干预措施: Lansoprazole (Drug)

Antacid alone

Active Comparator

Calcium carbonate/magnesium hydroxide

干预措施: Calcium carbonate/magnesium hydroxide (Drug)

结局指标

主要结局

Measure: Number of Participants With no Heartburn (Post Treatment) Following Consumption of Heartburn-inducing Meal

时间窗: 1 day

Participant reported severity of heartburn using a Visual Analog Scale (VAS)directly on CRF every 15 minutes until no heartburn reported or up to 5 hours after 1st heartburn-inducing meal, whichever occurred first. At this point in time, a diary was provided to participants to record any changes in severity of heartburn for 28 hours post treatment.

次要结局

  • Measure: Maximum Heartburn Intensity for Those Participants Who Experience Any Heartburn After the Heartburn-inducing Meals(1 day)
  • Measure: Maximum Heartburn Intensity for Those Participants Who Experience Any Nighttime Heartburn(1 day)
  • Measure: Number of Participants That Reported an Adverse Event for the Combination Product, PPI Alone, Antacid Alone and Placebo.(1 day)

研究者

发起方
Novartis
申办方类型
Industry

相似试验